382 related articles for article (PubMed ID: 25572615)
1. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
2. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.
Qi XH; Wu D; Cui HX; Ma N; Su J; Wang YT; Jiang YH
Mol Med Rep; 2014 Dec; 10(6):3177-84. PubMed ID: 25270552
[TBL] [Abstract][Full Text] [Related]
3. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
5. [The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma].
Xu Q; Cai W; Zhang M; Liu Q; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):387-92. PubMed ID: 26927562
[TBL] [Abstract][Full Text] [Related]
6. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
7. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
8. Lack of hepatic stimulator substance expression promotes hepatocellular carcinoma metastasis partly through ERK-activated epithelial-mesenchymal transition.
Jia XW; Li ZW; Dong LY; Sun GY; Wang X; Gao J; Li YP; Wu Y; An W
Lab Invest; 2018 Jul; 98(7):871-882. PubMed ID: 29497174
[TBL] [Abstract][Full Text] [Related]
9. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
11. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
12. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
13. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
[TBL] [Abstract][Full Text] [Related]
14. CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma.
Zhang XL; Huang CX; Zhang J; Inoue A; Zeng SE; Xiao SJ
Oncol Rep; 2013 Aug; 30(2):809-14. PubMed ID: 23756565
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
[TBL] [Abstract][Full Text] [Related]
16. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
18. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.
Hu WH; Hu Z; Shen X; Dong LY; Zhou WZ; Yu XX
Exp Mol Pathol; 2016 Feb; 100(1):101-8. PubMed ID: 26475622
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway.
Chen P; Lei L; Wang J; Zou X; Zhang D; Deng L; Wu D
Cancer Sci; 2017 Jun; 108(6):1157-1168. PubMed ID: 28375585
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition.
Zhou Y; Li Y; Ye J; Jiang R; Yan H; Yang X; Liu Q; Zhang J
Liver Int; 2013 Sep; 33(8):1271-80. PubMed ID: 23725476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
